MedTrace Logo

A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy

NCT04972201 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2305

Last updated 2024-12-27

No results posted yet for this study

Summary

PROMISE is a multi-center, prospective and proof of concept study aimed to evaluate the performance of 3 prototype assays of cell-free DNA (cfDNA) mutation, cfDNA methylation and microRNA (miRNA) expression in early detection of multi-cancer. Assay(s) will be selected for further development. The study will enroll approximately 2035 participants, including participants with cancers and healthy participants.

Conditions

Interventions

DEVICE

Multi-cancer early detection test

Blood collection and multi-cancer early detection test

Sponsors & Collaborators

  • Guangzhou Burning Rock Dx Co., Ltd.

    collaborator INDUSTRY

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jie Wang, M.D., Ph.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-03-31
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04972201 on ClinicalTrials.gov